Compile Data Set for Download or QSAR
Report error Found 326 Enz. Inhib. hit(s) with all data for entry = 5329
TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US9682983, 11 | US10017516, Compound 11)
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US9682983, 11 | US10017516, Compound 11)
Affinity DataIC50: 7.70nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161920(US9682983, 52 | US9682983, 53 | US10017516, Compou...)
Affinity DataIC50: 8nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US9682983, 11 | US10017516, Compound 11)
Affinity DataIC50: 9.20nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111123(US9682983, 2 | US10017516, Compound 2)
Affinity DataIC50: 10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM108945(US9682983, 48 | US10017516, Compound 48)
Affinity DataIC50: 11nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM127883(US9682983, 6 | US10017516, Compound 6)
Affinity DataIC50: 12nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161910(US9682983, 42 | US10017516, Compound 42)
Affinity DataIC50: 14nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160069(US9682983, 39 | US10017516, Compound 39)
Affinity DataIC50: 15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148348(US9682983, 22 | US10017516, Compound 22)
Affinity DataIC50: 15nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161914(US9682983, 46 | US10017516, Compound 46)
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US9682983, 13 | US10017516, Compound 13)
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 16nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161912(US9682983, 44 | US10017516, Compound 44)
Affinity DataIC50: 17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148371(US9682983, 32 | US10017516, Compound 32)
Affinity DataIC50: 17nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143207(US9682983, 7 | US10017516, Compound 7)
Affinity DataIC50: 19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US9682983, 10 | US10017516, Compound 10)
Affinity DataIC50: 19nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143246(US9682983, 8 | US10017516, Compound 8)
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148372(US9682983, 33 | US10017516, Compound 33)
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US9682983, 11 | US10017516, Compound 11)
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160478(US9682983, 41 | US10017516, Compound 41)
Affinity DataIC50: 22nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US9682983, 13 | US10017516, Compound 13)
Affinity DataIC50: 23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US9682983, 10 | US10017516, Compound 10)
Affinity DataIC50: 23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM127883(US9682983, 6 | US10017516, Compound 6)
Affinity DataIC50: 23nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148388(US9682983, 37 | US10017516, Compound 37)
Affinity DataIC50: 24nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143246(US9682983, 8 | US10017516, Compound 8)
Affinity DataIC50: 24nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143311(US9682983, 11 | US10017516, Compound 11)
Affinity DataIC50: 25nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143207(US9682983, 7 | US10017516, Compound 7)
Affinity DataIC50: 25nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148349(US9682983, 23 | US10017516, Compound 23)
Affinity DataIC50: 26nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM118134(US9682983, 3 | US10017516, Compound 3)
Affinity DataIC50: 27nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161925(US9682983, 57 | US10017516, Compound 57)
Affinity DataIC50: 28nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143566(US9682983, 13 | US10017516, Compound 13)
Affinity DataIC50: 29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 29nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148379(US9682983, 35 | US10017516, Compound 35)
Affinity DataIC50: 30nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161920(US9682983, 52 | US9682983, 53 | US10017516, Compou...)
Affinity DataIC50: 30nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148357(US9682983, 28 | US10017516, Compound 28)
Affinity DataIC50: 31nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160477(US9682983, 40 | US10017516, Compound 40)
Affinity DataIC50: 32nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161922(US9682983, 54 | US10017516, Compound 54)
Affinity DataIC50: 32nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161933(US9682983, 65 | US10017516, Compound 65)
Affinity DataIC50: 34nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148370(US9682983, 31 | US10017516, Compound 31)
Affinity DataIC50: 38nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM143282(US9682983, 10 | US10017516, Compound 10)
Affinity DataIC50: 38nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM111122(US9682983, 1 | US9682983, 17 | US10017516, Compoun...)
Affinity DataIC50: 40nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161929(US9682983, 61 | US10017516, Compound 61)
Affinity DataIC50: 41nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM160069(US9682983, 39 | US10017516, Compound 39)
Affinity DataIC50: 41nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM161927(US9682983, 59 | US10017516, Compound 59)
Affinity DataIC50: 43nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

Displayed 1 to 50 (of 326 total ) | Next | Last >>
Jump to: